In-stent Restenosis After Carotid Artery Stenting
Conditions
Keywords
Carotid Artery Disease, Carotid Artery Stenting, In stent restenosis, Cardiovascular event, Intima Media Thickness
Brief summary
CAS-CARE study was conducted to evaluate the inhibitory effect of cilostazol, compared to that of other antiplatelet drugs, on in-stent restenosis following carotid artery stenting (CAS) in patients scheduled to undergo CAS. Study design is Multicenter Prospective Ranodomized Controlled Study, rondomized by cilostazol/non-cilostazol group prior to CAS. 900 patients will be enrolled for 2 years and followed 2 years with in-stent restenosis after CAS, evaluated by carotid ultrasound and angiography.
Detailed description
Restenosis after carotid artery stenting (CAS) is a critical issue. Cilostazol can reduce restenosis after interventions in coronary or femoropopliteal arteries. The investigators confirmed and published periprocedural cilostazol administration reduced incidences of in-stent restenosis (ISR) or target vessel revascularization (TVR) after CAS, retrospectively. CAS-CARE study is Multicenter Prospective Ranodomized Controlled Study. Patients, scheduled for CAS within 30 days, 50% or more symptomatic carotid stenosis or 80% or more asymptomatic carotid stenosis, will enroll and randomize by cilostazol/non-cilostazol group. 900 patients will be enrolled for 2 years and followed 2 years with in-stent restenosis after CAS, evaluated by carotid ultrasound and angiography. And, evaluate cardiovascular events, including stroke, myocardial infarction, and hemorrhagic events in periprocedural period and followed period. In this study, ISR is diagnosed by ultrasound and DSA/CTA. Equivalence of CTA to ultrasound will be studied.
Interventions
DRUGCilostazol or Non-Cilostazol
Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
Sponsors
Chiba University
Nagoya University
Mie University
Wakayama Medical University
Kyoto University
Osaka University
Kobe University
Foundation for Biomedical Research and Innovation
Okayama University
Yamaguchi University Hospital
Fukuoka University
Nagasaki University
Kobe City General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 50% or more symptomatic carotid artery stenosis or 80% or more asymptomatic carotid artery stenosis * scheduled for carotid artery stenting within 30 days * 45 or more years-old and less than 80 years old * antiplatelet agents can be administratered orally * follow-up is anticipated possible for 2 years after CAS * self-supporoted in daily activities (modified Rankin Scale 2 or less) * patients who have given informed consent to participation in the study
Exclusion criteria
* received endovascular interevention * scheduled for bilateral carotid intervention * aortitis or cvasculitis * congessive heart failure * ischemic stroke within 48 hours * hemorrhagic stroke within 90 days * renal failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence or absence of in-stent restenosis within 2 years after CAS and time to occurrence | 2 years | Difinition of endpoint is 50% or more in-stent restenosis detected by carotid ultrasound or angiopraphy. In cases restenosis does not occur, the final observation point will be used as the final evaluation point. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| In-stent restenosis, new out-stent stenosis, or retreatment within 2 years | 2 years | In-stent restenosis, new out-stent stenosis detected by ultrasound or CTA/DSA, or retreatment of stented artery within 2 years |
| hemorrhagic event within 2 years | 2 years | hemorrhagic stroke, major hemorrhage required 2 unit or more transfusion |
| stroke within 2 years | 2 years | any ischemic or hemorrhagic stroke |
| Cardiovascular event, death, hemorrhagic event, in-stent restenosis, new out-stent stenosis, or retreatment of stented artery within 2 yrs | 2 years | Any events, including death, cardiovascular event(stroke, myocardial infarction), hemorrhagic event, in-stent restenosis, new out-stent stenosis, retreatment of stented artery, within 2 years |
| Severe in-stent restenosis within 2 yrs | 2 yeras | 70% or more in-stent restenosis, diagnosed by ultrasound or DSA/CTA, |
| Change from baseline in max-IMT in both common carotid arteries | 2 years | Intima-Media thickness of common carotid artery measured by ultrasound |
| In-stent restenosis, new out-stent stenosis, or retreatment of stented artery, cardiovascular event, or death from any cause within 30 days | 30 days | Any peri-procedural events; in-stent restenosis, new out-stent stenosis, or retreatment of stented artery, cardiovascular event(stroke, myocardial infarction), or death from any cause |
Countries
Japan
Outcome results
None listed